15.72
+0.28
+(1.81%)
At close: January 31 at 7:33:06 PM GMT+1
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Operating Cash Flow
-11,922.00
-11,922.00
-21,005.00
-21,362.00
-12,134.00
Investing Cash Flow
-613.00
-613.00
1,298.00
-316.00
-1,062.00
Financing Cash Flow
25,528.00
25,528.00
1,556.00
-800.00
47,917.00
End Cash Position
19,460.00
19,460.00
6,467.00
24,617.00
47,095.00
Capital Expenditure
-1,191.00
-1,191.00
-1,027.00
-1,974.00
-819.00
Issuance of Capital Stock
23,321.00
23,321.00
810.00
48.00
42,285.00
Issuance of Debt
13,843.00
13,843.00
29,976.00
3,308.00
18,706.00
Repayment of Debt
-8,767.00
-8,767.00
-24,148.00
-2,307.00
-9,265.00
Repurchase of Capital Stock
-25.00
-25.00
--
-192.00
--
Free Cash Flow
-13,113.00
-13,113.00
-22,032.00
-23,336.00
-12,953.00
3/31/2021 - 3/27/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IVA.PA Inventiva S.A.
2.3250
+0.43%
ENTBF Entheon Biomedical Corp.
0.2460
0.00%
NBTX Nanobiotix S.A.
3.4850
-1.83%
BNTC Benitec Biopharma Inc.
11.49
+5.32%
BIOA-B.ST BioArctic AB (publ)
220.60
-3.33%
RAPP Rapport Therapeutics, Inc.
16.41
-1.44%
CNTA Centessa Pharmaceuticals plc
16.92
+0.06%
LXEO Lexeo Therapeutics, Inc.
5.43
+3.43%
NGNE Neurogene Inc.
15.85
+2.06%
GHRS GH Research PLC
10.60
+9.39%